Tunable reversir tm compounds
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsIvan ZLATEV, Adam CASTORENO, Martin MAIER, Vasant JADHAV, Jae KIM, Pushkal GARG
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.
Claims20
A tunable REVERSIR compound comprising 8 or 9 modified nucleotides, wherein at least three of the modified nucleotides are high affinity monomers and one of the high affinity monomers is base paired with the 6th nucleotide from the 5′-end of the target strand of the siRNA.
Dependencies are inferred from the claim text.